Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

10x Genomics (TXG) Other Gross PP&E Adjustments (2018 - 2026)

10x Genomics' Other Gross PP&E Adjustments history spans 8 years, with the latest figure at $295.3 million for Q4 2025.

  • On a quarterly basis, Other Gross PP&E Adjustments rose 1.3% to $295.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $295.3 million, a 1.3% increase, with the full-year FY2025 number at $295.3 million, up 1.3% from a year prior.
  • Other Gross PP&E Adjustments hit $295.3 million in Q4 2025 for 10x Genomics, down from $314.7 million in the prior quarter.
  • Over the last five years, Other Gross PP&E Adjustments for TXG hit a ceiling of $323.8 million in Q3 2024 and a floor of -$75.7 million in Q1 2022.
  • Historically, Other Gross PP&E Adjustments has averaged $191.7 million across 5 years, with a median of $292.5 million in 2023.
  • Biggest five-year swings in Other Gross PP&E Adjustments: tumbled 190.35% in 2022 and later skyrocketed 535.6% in 2023.
  • Tracing TXG's Other Gross PP&E Adjustments over 5 years: stood at $145.3 million in 2021, then surged by 83.97% to $267.4 million in 2022, then grew by 9.72% to $293.4 million in 2023, then dropped by 0.62% to $291.6 million in 2024, then rose by 1.3% to $295.3 million in 2025.
  • Business Quant data shows Other Gross PP&E Adjustments for TXG at $295.3 million in Q4 2025, $314.7 million in Q3 2025, and $316.8 million in Q2 2025.